Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LPRI-424 vs drospirenone/ethinyl estradiol for oral contraception
2019-001877-97Phase 3Completed
- Sponsor
- Chemo
- Start
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of dienogest + ethinyl estradiol (2 arms), sponsored by Chemo. Primary endpoint: Overall Pearl Index in women aged ≤35 years. Started Dec 2019; status: completed.
02
Drugs
dienogest + ethinyl estradiol
Beyond the preview
Go deeper on 2019-001877-97.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001877-97.